Ocular Therapeutix (OCUL) Stock Forecast, Price Target & Predictions
OCUL Stock Forecast
Ocular Therapeutix stock forecast is as follows: an average price target of $17.50 (represents a 94.44% upside from OCUL’s last price of $9.00) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
OCUL Price Target
The average price target for Ocular Therapeutix (OCUL) is $17.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $24.00 to $14.00. This represents a potential 94.44% upside from OCUL's last price of $9.00.
OCUL Analyst Ratings
According to 4 Wall Street analysts, Ocular Therapeutix's rating consensus is 'Buy'. The analyst rating breakdown for OCUL stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Ocular Therapeutix Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | Colleen Kusy | Robert W. Baird | $17.00 | $8.37 | 103.11% | 88.89% |
| Jun 27, 2024 | Biren Amin | Piper Sandler | $15.00 | $6.71 | 123.55% | 66.67% |
| Jun 14, 2024 | Yi Chen | H.C. Wainwright | $14.00 | $5.89 | 137.77% | 55.56% |
| Mar 12, 2024 | Jonathan Wolleben | JMP Securities | $24.00 | $9.29 | 158.34% | 166.67% |
| Jun 07, 2022 | Joseph Catanzaro | Piper Sandler | $10.00 | $3.78 | 164.55% | 11.11% |
The latest Ocular Therapeutix stock forecast, released on Aug 08, 2024 by Colleen Kusy from Robert W. Baird, set a price target of $17.00, which represents a 103.11% increase from the stock price at the time of the forecast ($8.37), and a 88.89% increase from OCUL last price ($9.00).
Ocular Therapeutix Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 4 |
| Avg Price Target | - | $16.00 | $17.50 |
| Last Closing Price | $9.00 | $9.00 | $9.00 |
| Upside/Downside | -100.00% | 77.78% | 94.44% |
In the current month, the average price target of Ocular Therapeutix stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ocular Therapeutix's last price of $9.00. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 01, 2024 | Sandler O'Neil | Underperform | Underperform | Hold |
| Aug 01, 2024 | Sandler O'Neill | Market Outperform | Market Outperform | Hold |
| Jun 27, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 20, 2024 | Cowen & Co. | Hold | Buy | Upgrade |
| Jun 14, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Jun 14, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jun 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 14, 2024 | Cowen & Co. | Hold | Hold | Hold |
| May 08, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Apr 16, 2024 | JMP Securities | Underperform | Underperform | Hold |
Ocular Therapeutix's last stock rating was published by Sandler O'Neil on Aug 01, 2024. The company gave OCUL a "Underperform" rating, the same as its previous rate.
Ocular Therapeutix Financial Forecast
Ocular Therapeutix Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $14.80M | $14.95M | $15.03M | $13.37M | $14.08M | $11.96M | - | $13.19M | $12.31M | $12.15M | $11.72M | $7.34M | $7.35M | $5.88M | $1.57M | $2.61M | $2.26M | $829.00K |
| Avg Forecast | $20.90M | $20.60M | $20.30M | $20.00M | $18.25M | $18.01M | $17.73M | $17.37M | $17.75M | $17.13M | $15.85M | $15.36M | $15.70M | $15.23M | $14.62M | $14.09M | $13.53M | $14.27M | $14.25M | $13.96M | $13.94M | $12.45M | $10.82M | $7.64M | $7.73M | $5.50M | $1.50M | $2.66M | $2.19M | $580.00K |
| High Forecast | $23.18M | $22.85M | $22.52M | $22.18M | $20.24M | $19.97M | $19.66M | $19.26M | $19.69M | $18.41M | $17.58M | $17.04M | $16.11M | $16.89M | $16.22M | $15.63M | $15.01M | $15.83M | $14.25M | $14.35M | $14.34M | $12.81M | $11.13M | $7.85M | $7.95M | $5.66M | $1.54M | $2.73M | $2.26M | $596.47K |
| Low Forecast | $19.03M | $18.76M | $18.49M | $18.21M | $16.62M | $16.40M | $16.14M | $15.81M | $16.17M | $16.30M | $14.43M | $13.99M | $15.09M | $13.87M | $13.32M | $12.83M | $12.32M | $13.00M | $14.25M | $13.50M | $13.48M | $12.04M | $10.47M | $7.39M | $7.48M | $5.32M | $1.45M | $2.57M | $2.12M | $560.91K |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 6 | 10 | 10 | 10 | 10 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.94% | 0.98% | 1.03% | 0.95% | 1.04% | 0.84% | - | 0.94% | 0.88% | 0.98% | 1.08% | 0.96% | 0.95% | 1.07% | 1.05% | 0.98% | 1.03% | 1.43% |
Ocular Therapeutix's average Quarter revenue forecast for Mar 24 based on 4 analysts is $15.36M, with a low forecast of $13.99M, and a high forecast of $17.04M. OCUL's average Quarter revenue forecast represents a 3.79% increase compared to the company's last Quarter revenue of $14.80M (Dec 23).
Ocular Therapeutix EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 6 | 10 | 10 | 10 | 10 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-19.09M | $-19.21M | $-20.57M | $-21.99M | $-18.94M | $-20.75M | - | $-17.26M | $-18.04M | $4.91M | $-6.21M | $5.45M | $-83.22M | $-9.56M | $-34.17M | $-19.14M | $-23.54M | $-16.46M |
| Avg Forecast | $-20.90M | $-20.60M | $-20.30M | $-20.00M | $-18.25M | $-18.01M | $-17.73M | $-17.37M | $-17.75M | $-17.13M | $-15.85M | $-17.26M | $-15.70M | $-15.23M | $-14.62M | $-15.69M | $-13.53M | $10.28M | $-14.25M | $-14.26M | $-23.97M | $9.35M | $-4.66M | $-7.64M | $-7.73M | $-10.76M | $-26.07M | $-17.08M | $-2.19M | $-18.91M |
| High Forecast | $-19.03M | $-18.76M | $-18.49M | $-18.21M | $-16.62M | $-16.40M | $-16.14M | $-15.81M | $-16.17M | $-16.30M | $-14.43M | $-13.81M | $-15.09M | $-13.87M | $-13.32M | $-12.55M | $-12.32M | $12.34M | $-14.25M | $-11.41M | $-19.18M | $11.22M | $-3.73M | $-7.39M | $-7.48M | $-8.61M | $-20.85M | $-13.66M | $-2.12M | $-15.13M |
| Low Forecast | $-23.18M | $-22.85M | $-22.52M | $-22.18M | $-20.24M | $-19.97M | $-19.66M | $-19.26M | $-19.69M | $-18.41M | $-17.58M | $-20.71M | $-16.11M | $-16.89M | $-16.22M | $-18.83M | $-15.01M | $8.22M | $-14.25M | $-17.12M | $-28.77M | $7.48M | $-5.59M | $-7.85M | $-7.95M | $-12.91M | $-31.28M | $-20.49M | $-2.26M | $-22.69M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.22% | 1.26% | 1.41% | 1.40% | 1.40% | -2.02% | - | 1.21% | 0.75% | 0.53% | 1.33% | -0.71% | 10.77% | 0.89% | 1.31% | 1.12% | 10.72% | 0.87% |
2 analysts predict OCUL's average Quarter EBITDA for Dec 21 to be $-23.97M, with a high of $-19.18M and a low of $-28.77M. This is -588.36% lower than Ocular Therapeutix's previous annual EBITDA (Sep 21) of $4.91M.
Ocular Therapeutix Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 6 | 10 | 10 | 10 | 10 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-29.22M | $-516.00K | $-20.68M | $-36.40M | $-11.72M | $-26.83M | - | $-7.25M | $-5.53M | $2.66M | $-8.48M | $3.12M | $-85.61M | $-11.94M | $-36.57M | $-21.51M | $-26.02M | $-18.78M |
| Avg Forecast | $-64.67M | $-58.04M | $-53.06M | $-48.09M | $-44.11M | $-41.79M | $-40.79M | $-39.80M | $-37.10M | $-40.42M | $-36.69M | $-21.01M | $-49.13M | $-47.61M | $-49.98M | $-19.10M | $-42.01M | $5.56M | $-29.31M | $-17.37M | $-6.18M | $5.06M | $-6.36M | $6.15M | $-14.07M | $-13.44M | $-27.90M | $-19.19M | $-35.46M | $-21.57M |
| High Forecast | $-57.16M | $-51.30M | $-46.90M | $-42.51M | $-38.99M | $-36.94M | $-36.06M | $-35.18M | $-32.80M | $-36.90M | $-32.43M | $-16.81M | $-31.58M | $-42.09M | $-44.18M | $-15.28M | $-37.13M | $6.68M | $-29.31M | $-13.89M | $-4.94M | $6.07M | $-5.09M | $7.38M | $-13.47M | $-10.75M | $-22.32M | $-15.35M | $-33.94M | $-17.26M |
| Low Forecast | $-73.85M | $-66.28M | $-60.59M | $-54.91M | $-50.37M | $-47.72M | $-46.58M | $-45.45M | $-42.37M | $-52.72M | $-41.90M | $-25.22M | $-94.74M | $-54.37M | $-57.08M | $-22.92M | $-47.97M | $4.45M | $-29.31M | $-20.84M | $-7.41M | $4.05M | $-7.63M | $4.92M | $-14.59M | $-16.12M | $-33.48M | $-23.02M | $-36.77M | $-25.89M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.59% | 0.01% | 0.41% | 1.91% | 0.28% | -4.82% | - | 0.42% | 0.90% | 0.53% | 1.33% | 0.51% | 6.08% | 0.89% | 1.31% | 1.12% | 0.73% | 0.87% |
Ocular Therapeutix's average Quarter net income forecast for Dec 21 is $-6.18M, with a range of $-7.41M to $-4.94M. OCUL's average Quarter net income forecast represents a -332.47% decrease compared to the company's last Quarter net income of $2.66M (Sep 21).
Ocular Therapeutix SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 6 | 10 | 10 | 10 | 10 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $17.27M | $17.90M | $19.36M | $19.96M | $18.88M | $18.72M | - | $16.62M | $16.67M | $17.65M | $16.99M | $15.75M | $13.39M | $12.48M | $11.30M | $12.31M | $12.69M | $12.93M |
| Avg Forecast | $75.60M | $74.52M | $73.43M | $72.35M | $66.00M | $65.13M | $64.12M | $62.82M | $64.22M | $61.98M | $57.33M | $55.57M | $56.80M | $55.09M | $52.90M | $50.98M | $48.96M | $51.62M | $51.54M | $50.49M | $50.43M | $45.05M | $39.16M | $27.62M | $27.96M | $19.90M | $5.42M | $9.61M | $7.94M | $2.10M |
| High Forecast | $83.86M | $82.65M | $81.45M | $80.25M | $73.21M | $72.24M | $71.12M | $69.68M | $71.24M | $66.61M | $63.59M | $61.64M | $58.29M | $61.10M | $58.68M | $56.54M | $54.30M | $57.26M | $51.54M | $51.92M | $51.86M | $46.33M | $40.27M | $28.41M | $28.76M | $20.47M | $5.58M | $9.88M | $8.17M | $2.16M |
| Low Forecast | $68.85M | $67.86M | $66.87M | $65.89M | $60.11M | $59.32M | $58.39M | $57.21M | $58.49M | $58.96M | $52.21M | $50.61M | $54.58M | $50.17M | $48.18M | $46.42M | $44.58M | $47.01M | $51.54M | $48.83M | $48.77M | $43.57M | $37.87M | $26.72M | $27.04M | $19.25M | $5.24M | $9.29M | $7.68M | $2.03M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.30% | 0.32% | 0.37% | 0.39% | 0.39% | 0.36% | - | 0.33% | 0.33% | 0.39% | 0.43% | 0.57% | 0.48% | 0.63% | 2.08% | 1.28% | 1.60% | 6.16% |
Ocular Therapeutix's average Quarter SG&A projection for Mar 24 is $55.57M, based on 4 Wall Street analysts, with a range of $50.61M to $61.64M. The forecast indicates a 221.78% rise compared to OCUL last annual SG&A of $17.27M (Dec 23).
Ocular Therapeutix EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 6 | 10 | 10 | 10 | 10 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.35 | $-0.01 | $-0.00 | $-0.47 | $-0.15 | $-0.35 | - | $-0.09 | $-0.07 | $0.03 | $-0.11 | $0.04 | $-1.21 | $-0.19 | $-0.64 | $-0.41 | $-0.53 | $-0.40 |
| Avg Forecast | $-0.39 | $-0.35 | $-0.32 | $-0.29 | $-0.27 | $-0.25 | $-0.25 | $-0.24 | $-0.22 | $-0.24 | $-0.22 | $-0.19 | $-0.30 | $-0.29 | $-0.30 | $-0.26 | $-0.25 | $-0.24 | $-0.22 | $-0.23 | $-0.23 | $-0.26 | $-0.21 | $-0.21 | $-0.17 | $-0.24 | $-0.30 | $-0.37 | $-0.42 | $-0.51 |
| High Forecast | $-0.34 | $-0.31 | $-0.28 | $-0.26 | $-0.24 | $-0.22 | $-0.22 | $-0.21 | $-0.20 | $-0.22 | $-0.20 | $-0.17 | $-0.19 | $-0.25 | $-0.27 | $-0.23 | $-0.22 | $-0.21 | $-0.22 | $-0.22 | $-0.22 | $-0.25 | $-0.20 | $-0.20 | $-0.16 | $-0.23 | $-0.29 | $-0.35 | $-0.40 | $-0.48 |
| Low Forecast | $-0.45 | $-0.40 | $-0.37 | $-0.33 | $-0.30 | $-0.29 | $-0.28 | $-0.27 | $-0.26 | $-0.32 | $-0.25 | $-0.22 | $-0.57 | $-0.33 | $-0.34 | $-0.30 | $-0.29 | $-0.27 | $-0.22 | $-0.24 | $-0.24 | $-0.27 | $-0.22 | $-0.21 | $-0.17 | $-0.25 | $-0.31 | $-0.38 | $-0.44 | $-0.53 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.18% | 0.03% | 0.00% | 1.78% | 0.59% | 1.47% | - | 0.40% | 0.31% | -0.12% | 0.52% | -0.19% | 7.26% | 0.79% | 2.13% | 1.11% | 1.26% | 0.79% |
According to 2 Wall Street analysts, Ocular Therapeutix's projected average Quarter EPS for Dec 21 is $-0.23, with a low estimate of $-0.24 and a high estimate of $-0.22. This represents a -880.00% decrease compared to OCUL previous annual EPS of $0.03 (Sep 21).
Ocular Therapeutix Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.37 | $10.00 | 629.93% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| CTMX | CytomX Therapeutics | $1.23 | $5.77 | 369.11% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| ACHL | Achilles Therapeutics | $0.72 | $2.00 | 177.78% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| OCUL | Ocular Therapeutix | $9.00 | $17.50 | 94.44% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
OCUL Forecast FAQ
Is Ocular Therapeutix a good buy?
Yes, according to 4 Wall Street analysts, Ocular Therapeutix (OCUL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of OCUL's total ratings.
What is OCUL's price target?
Ocular Therapeutix (OCUL) average price target is $17.5 with a range of $14 to $24, implying a 94.44% from its last price of $9. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Ocular Therapeutix stock go up soon?
According to Wall Street analysts' prediction for OCUL stock, the company can go up by 94.44% (from the last price of $9 to the average price target of $17.5), up by 166.67% based on the highest stock price target, and up by 55.56% based on the lowest stock price target.
Can Ocular Therapeutix stock reach $14?
OCUL's average twelve months analyst stock price target of $17.5 supports the claim that Ocular Therapeutix can reach $14 in the near future.
What are Ocular Therapeutix's analysts' financial forecasts?
Ocular Therapeutix's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $71.34M (high $79.13M, low $64.97M), average EBITDA is $-71.344M (high $-64.972M, low $-79.132M), average net income is $-166M (high $-147M, low $-190M), average SG&A $258.08M (high $286.25M, low $235.03M), and average EPS is $-1.004 (high $-0.887, low $-1.146). OCUL's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $81.8M (high $90.73M, low $74.49M), average EBITDA is $-81.8M (high $-74.494M, low $-90.73M), average net income is $-224M (high $-198M, low $-256M), average SG&A $295.9M (high $328.2M, low $269.47M), and average EPS is $-1.35 (high $-1.193, low $-1.542).
Did the OCUL's actual financial results beat the analysts' financial forecasts?
Based on Ocular Therapeutix's last annual report (Dec 2023), the company's revenue was $57.87M, which missed the average analysts forecast of $59.65M by -2.98%. Apple's EBITDA was $-82.382M, beating the average prediction of $-61.246M by 34.51%. The company's net income was $-80.736M, missing the average estimation of $-166M by -51.31%. Apple's SG&A was $74.49M, missing the average forecast of $215.77M by -65.48%. Lastly, the company's EPS was $-0.0009, missing the average prediction of $-1.148 by -99.92%. In terms of the last quarterly report (Dec 2023), Ocular Therapeutix's revenue was $14.8M, missing the average analysts' forecast of $15.7M by -5.74%. The company's EBITDA was $-19.091M, beating the average prediction of $-15.703M by 21.58%. Ocular Therapeutix's net income was $-29.22M, missing the average estimation of $-49.126M by -40.52%. The company's SG&A was $17.27M, missing the average forecast of $56.8M by -69.60%. Lastly, the company's EPS was $-0.35, beating the average prediction of $-0.296 by 18.14%